Autologous Stem Cell Mobilization in the Age of Plerixafor

Dennis L. Cooper, Erin Medoff, Natalie Patel, Julie Baker, Kathryn Pratt, Francine Foss, Stuart E. Seropian, Sarah Perreault, Yanyun Wu

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


Plerixafor is a potent stem cell–mobilizing agent whose cost is prohibitive for routine use. In 277 consecutive patients, the addition of rescue plerixafor during suboptimal granulocyte-colony stimulating factor (G-CSF) mobilization or after prior failure of chemotherapy plus G-CSF was associated with successful mobilization in 97.5% of patients, with target collections achieved in 60% of lymphoma and 72% of myeloma patients. Background Autologous stem cell transplantation remains important in the treatment of myeloma and relapsed lymphoma. Plerixafor has been shown to significantly enhance stem cell mobilization but is very expensive. Patients and Methods We evaluated plerixafor use in the 3-year period after its approval in December 2008. Results A total of 277 patients with myeloma and lymphoma had stem cell mobilization; 97.5% were successfully mobilized, including 41.5% who received plerixafor. Plerixafor was generally used for rescue after suboptimal granulocyte-colony stimulating factor (G-CSF) mobilization (“just in time”) or for remobilization after an unsuccessful attempt with chemotherapy plus G-CSF. In addition, 10% of patients received planned G-CSF plus plerixafor because of high risk factors for inadequate collection. Rescue plerixafor was more effective in patients with myeloma than lymphoma as after 1 dose of plerixafor; 85% versus 55% collected a minimum number of stem cells (2 × 10E6 CD34 cells/kg) for 1 transplant and 51% versus 15% collected > 5 × 10E6 CD34 cells/kg. After transplantation, there were no significant differences in engraftment as a consequence of plerixafor use. Among all patients, there were less platelet transfusions in patients provided ≥ 3.5 × 10E6 CD34+ cells/kg. Conclusion With the judicious use of plerixafor, nearly all patients can collect enough stem cells to proceed to transplantation. Further studies, including hematologic tolerance to posttransplantation therapy, are required to determine the cost-effectiveness of using plerixafor to convert adequate to more optimal mobilizers.

Original languageEnglish (US)
Pages (from-to)411-416
Number of pages6
JournalClinical Lymphoma, Myeloma and Leukemia
Issue number7
StatePublished - Jul 1 2016
Externally publishedYes


  • Growth factors
  • Hematopoietic stem cell transplantation
  • Multiple myeloma
  • Plerixafor
  • Stem cell mobilization

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Autologous Stem Cell Mobilization in the Age of Plerixafor'. Together they form a unique fingerprint.

Cite this